Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/38519
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorFONSECA, Leonardo G. da
dc.contributor.authorREIG, Maria
dc.contributor.authorBRUIX, Jordi
dc.date.accessioned2020-12-16T14:57:19Z-
dc.date.available2020-12-16T14:57:19Z-
dc.date.issued2020
dc.identifier.citationCLINICS IN LIVER DISEASE, v.24, n.4, p.719-737, 2020
dc.identifier.issn1089-3261
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/38519-
dc.language.isoeng
dc.publisherW B SAUNDERS CO-ELSEVIER INCeng
dc.relation.ispartofClinics in Liver Disease
dc.rightsrestrictedAccesseng
dc.subjectHepatocellular carcinomaeng
dc.subjectTyrosine kinaseeng
dc.subjectSystemic treatmenteng
dc.subjectSorafenibeng
dc.subjectLenvatinibeng
dc.subjectCabozantinibeng
dc.subjectRegorafenibeng
dc.subject.otherendothelial growth-factoreng
dc.subject.otherphase-iiieng
dc.subject.otherprotein-kinaseeng
dc.subject.otherdouble-blindeng
dc.subject.othertreatment efficacyeng
dc.subject.other1st-line therapyeng
dc.subject.otherplus erlotinibeng
dc.subject.othersorafenibeng
dc.subject.othercancereng
dc.subject.othersurvivaleng
dc.titleTyrosine Kinase Inhibitors and Hepatocellular Carcinomaeng
dc.typearticleeng
dc.rights.holderCopyright W B SAUNDERS CO-ELSEVIER INCeng
dc.identifier.doi10.1016/j.cld.2020.07.012
dc.identifier.pmid33012455
dc.subject.wosGastroenterology & Hepatologyeng
dc.type.categoryrevieweng
dc.type.versionpublishedVersioneng
hcfmusp.author.externalREIG, Maria:Hosp Clin Barcelona, Liver Unit, Barcelona Clin Liver Canc BCLC Grp, IDIBAPS, Villarroel 170, Barcelona 08036, Spain; Univ Barcelona, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Barcelona, Spain
hcfmusp.author.externalBRUIX, Jordi:Hosp Clin Barcelona, Liver Unit, Barcelona Clin Liver Canc BCLC Grp, IDIBAPS, Villarroel 170, Barcelona 08036, Spain; Univ Barcelona, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Barcelona, Spain
hcfmusp.description.beginpage719
hcfmusp.description.endpage737
hcfmusp.description.issue4
hcfmusp.description.volume24
hcfmusp.origemWOS
hcfmusp.origem.idWOS:000582503300012
hcfmusp.origem.id2-s2.0-85090305482
hcfmusp.publisher.cityPHILADELPHIAeng
hcfmusp.publisher.countryUSAeng
hcfmusp.relation.referenceAbou-Alfa GK, 2006, J CLIN ONCOL, V24, P4293, DOI 10.1200/JCO.2005.01.3441eng
hcfmusp.relation.referenceAbou-Alfa GK, 2019, JAMA ONCOL, V5, P1582, DOI 10.1001/jamaoncol.2019.2792eng
hcfmusp.relation.referenceAbou-Alfa GK, 2010, JAMA-J AM MED ASSOC, V304, P2154, DOI 10.1001/jama.2010.1672eng
hcfmusp.relation.referenceArora A, 2005, J PHARMACOL EXP THER, V315, P971, DOI 10.1124/jpet.105.084145eng
hcfmusp.relation.referenceBosch J, 2010, J HEPATOL, V53, P558, DOI 10.1016/j.jhep.2010.03.021eng
hcfmusp.relation.referenceBruix J, 2019, NAT REV GASTRO HEPAT, V16, P617, DOI 10.1038/s41575-019-0179-xeng
hcfmusp.relation.referenceBruix J, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.4_suppl.412eng
hcfmusp.relation.referenceBruix J, 2017, J HEPATOL, V67, P999, DOI 10.1016/j.jhep.2017.06.026eng
hcfmusp.relation.referenceBruix J, 2017, J HEPATOL, V66, P1114, DOI 10.1016/j.jhep.2017.02.032eng
hcfmusp.relation.referenceBruix J, 2017, LANCET, V389, P56, DOI 10.1016/S0140-6736(16)32453-9eng
hcfmusp.relation.referenceCainap C, 2015, J CLIN ONCOL, V33, P172, DOI 10.1200/JCO.2013.54.3298eng
hcfmusp.relation.referenceChao Y, 2003, ANN SURG ONCOL, V10, P355, DOI 10.1245/ASO.2003.10.002eng
hcfmusp.relation.referenceChen SZ, 2019, CANCER LETT, V460, P1, DOI 10.1016/j.canlet.2019.114428eng
hcfmusp.relation.referenceCheng AL, 2013, J CLIN ONCOL, V31, P4067, DOI 10.1200/JCO.2012.45.8372eng
hcfmusp.relation.referenceCheng AL, 2009, LANCET ONCOL, V10, P25, DOI 10.1016/S1470-2045(08)70285-7eng
hcfmusp.relation.referenceCOLLETT MS, 1978, P NATL ACAD SCI USA, V75, P2021, DOI 10.1073/pnas.75.4.2021eng
hcfmusp.relation.referenceCOUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548eng
hcfmusp.relation.referenceDiaz-Gonzalez A, 2019, ALIMENT PHARM THER, V49, P482, DOI 10.1111/apt.15088eng
hcfmusp.relation.referenceEuropean Assoc Study Liver, 2018, J HEPATOL, V69, P182, DOI 10.1016/j.jhep.2018.03.019eng
hcfmusp.relation.referenceFinn RS, 2020, NEW ENGL J MED, V382, P1894, DOI 10.1056/NEJMoa1915745eng
hcfmusp.relation.referenceFirtina K. Z., 2016, CANCER SCI, V107, P407, DOI 10.1111/cas.12891eng
hcfmusp.relation.referenceGuichard C, 2012, NAT GENET, V44, P694, DOI 10.1038/ng.2256eng
hcfmusp.relation.referenceHage C, 2019, HEPATOLOGY, V70, P1280, DOI 10.1002/hep.30666eng
hcfmusp.relation.referenceHanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013eng
hcfmusp.relation.referenceHIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032eng
hcfmusp.relation.referenceHopkin MD, 2010, CHEM COMMUN, V46, P2450, DOI 10.1039/c001550deng
hcfmusp.relation.referenceHu G, 2018, ONCOL LETT, V16, P3439, DOI 10.3892/ol.2018.9078eng
hcfmusp.relation.referenceHuynh H, 2003, BMC GASTROENTEROL, V19, P1eng
hcfmusp.relation.referenceIkeda K, 2017, J GASTROENTEROL, V52, P512, DOI 10.1007/s00535-016-1263-4eng
hcfmusp.relation.referenceJohnson PJ, 2013, J CLIN ONCOL, V31, P3517, DOI 10.1200/JCO.2012.48.4410eng
hcfmusp.relation.referenceKaseb AO, 2012, ONCOLOGY-BASEL, V82, P67, DOI 10.1159/000335963eng
hcfmusp.relation.referenceKato Y, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212513eng
hcfmusp.relation.referenceKittler H, 2018, BRIT J DERMATOL, V178, P26, DOI 10.1111/bjd.16119eng
hcfmusp.relation.referenceKudo M, 2020, GUT, V69, P1492, DOI 10.1136/gutjnl-2019-318934eng
hcfmusp.relation.referenceKudo M, 2018, LANCET, V391, P1163, DOI 10.1016/S0140-6736(18)30207-1eng
hcfmusp.relation.referenceKudo M, 2014, HEPATOLOGY, V60, P1697, DOI 10.1002/hep.27290eng
hcfmusp.relation.referenceLencioni R, 2016, J HEPATOL, V64, P1090, DOI 10.1016/j.jhep.2016.01.012eng
hcfmusp.relation.referenceLencioni R, 2010, SEMIN LIVER DIS, V30, P52, DOI 10.1055/s-0030-1247132eng
hcfmusp.relation.referenceLLOVET JM, 2019, J CLIN ONCOL S, V37eng
hcfmusp.relation.referenceLlovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857eng
hcfmusp.relation.referenceLlovet JM, 2013, J CLIN ONCOL, V31, P3509, DOI 10.1200/JCO.2012.47.3009eng
hcfmusp.relation.referenceLlovet JM, 2012, CLIN CANCER RES, V18, P2290, DOI 10.1158/1078-0432.CCR-11-2175eng
hcfmusp.relation.referenceMarrero JA, 2016, J HEPATOL, V65, P1140, DOI 10.1016/j.jhep.2016.07.020eng
hcfmusp.relation.referenceMaurer G, 2011, ONCOGENE, V30, P3477, DOI 10.1038/onc.2011.160eng
hcfmusp.relation.referenceMedical Advisory Secretariat, 2010, Ont Health Technol Assess Ser, V10, P1eng
hcfmusp.relation.referenceMohanlal RW, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.7_suppl.139eng
hcfmusp.relation.referenceMorgan RL, 2018, J THORAC ONCOL, V13, P154, DOI 10.1016/j.jtho.2017.10.015eng
hcfmusp.relation.referenceMotzer RJ, 2006, EXPERT OPIN INV DRUG, V15, P553, DOI 10.1517/13543784.15.5.553eng
hcfmusp.relation.referencePark JW, 2019, J HEPATOL, V70, P684, DOI 10.1016/j.jhep.2018.11.029eng
hcfmusp.relation.referencePaschalis G, 2013, SURG CHRONICLES, V18, P134eng
hcfmusp.relation.referenceRankin EB, 2016, CANCERS, V8, DOI 10.3390/cancers8110103eng
hcfmusp.relation.referenceReig M, 2014, J HEPATOL, V61, P318, DOI 10.1016/j.jhep.2014.03.030eng
hcfmusp.relation.referenceReig M, 2013, HEPATOLOGY, V58, P2023, DOI 10.1002/hep.26586eng
hcfmusp.relation.referenceRicke J, 2018, J HEPATOL, V68, pS102, DOI 10.1016/S0168-8278(18)30424-0eng
hcfmusp.relation.referenceRimassa L, 2018, LANCET ONCOL, V19, P682, DOI 10.1016/S1470-2045(18)30146-3eng
hcfmusp.relation.referenceRimola J, 2018, HEPATOLOGY, V67, P612, DOI 10.1002/hep.29515eng
hcfmusp.relation.referenceShao YY, 2010, CANCER-AM CANCER SOC, V116, P4590, DOI 10.1002/cncr.25257eng
hcfmusp.relation.referenceStrumberg D, 2005, J CLIN ONCOL, V23, P965, DOI 10.1200/JCO.2005.06.124eng
hcfmusp.relation.referenceTai WT, 2012, MOL CANCER THER, V11, P452, DOI 10.1158/1535-7163.MCT-11-0412eng
hcfmusp.relation.referenceTHOMAS MB, 2015, J CLIN ONCOL S, V33eng
hcfmusp.relation.referenceVennepureddy A, 2017, J ONCOL PHARM PRACT, V23, P525, DOI 10.1177/1078155216655474eng
hcfmusp.relation.referenceVillanueva A, 2019, NEW ENGL J MED, V380, P1450, DOI 10.1056/NEJMra1713263eng
hcfmusp.relation.referenceVillanueva A, 2008, GASTROENTEROLOGY, V135, P1972, DOI 10.1053/j.gastro.2008.08.008eng
hcfmusp.relation.referenceVoron T, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00070eng
hcfmusp.relation.referenceWang B, 2008, ACTA RADIOL, V49, P523, DOI 10.1080/02841850801958890eng
hcfmusp.relation.referenceWilhelm SM, 2011, INT J CANCER, V129, P245, DOI 10.1002/ijc.25864eng
hcfmusp.relation.referenceWilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443eng
hcfmusp.relation.referenceZhao XX, 2016, INNATE IMMUN-LONDON, V22, P493, DOI 10.1177/1753425916659702eng
hcfmusp.relation.referenceZhu AX, 2019, LANCET ONCOL, V20, P282, DOI 10.1016/S1470-2045(18)30937-9eng
hcfmusp.relation.referenceZhu AX, 2015, LANCET ONCOL, V16, P859, DOI 10.1016/S1470-2045(15)00050-9eng
hcfmusp.relation.referenceZhu AX, 2015, J CLIN ONCOL, V33, P559, DOI 10.1200/JCO.2013.53.7746eng
hcfmusp.relation.referenceZocco MA, 2013, J HEPATOL, V59, P1014, DOI 10.1016/j.jhep.2013.06.011eng
dc.description.indexMEDLINEeng
dc.identifier.eissn1557-8224
hcfmusp.citation.scopus12-
hcfmusp.scopus.lastupdate2022-04-28-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - HC/ICESP
Instituto do Câncer do Estado de São Paulo - HC/ICESP

Artigos e Materiais de Revistas Científicas - ODS/03
ODS/03 - Saúde e bem-estar


Files in This Item:
File Description SizeFormat 
art_FONSECA_Tyrosine_Kinase_Inhibitors_and_Hepatocellular_Carcinoma_2020.PDF.pdf
  Restricted Access
publishedVersion (English)894.29 kBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.